Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other neoplasm 1

Conditions

Precancerous Conditions 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Surveys and Questionnaires 9Cyclophosphamide 9Whole-Body Irradiation 7Biopsy 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Educational Status 6Early Intervention, Educational 6Busulfan 6Methotrexate 5Methods 5Immunohistochemistry 5Epoetin Alfa 5Tacrolimus 4Mycophenolic Acid 4Interviews as Topic 4Gene Expression Profiling 4Decitabine 4Cyclosporine 4Celecoxib 4Antilymphocyte Serum 4fludarabine 3Sirolimus 3Radiotherapy 3Paclitaxel 3Microarray Analysis 3Melphalan 3Magnetic Resonance Spectroscopy 3Imiquimod 3Fentanyl 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Iloprost × Other neoplasm × Clear all
NCT00084409 2020-05-14

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

University of Colorado, Denver

Phase 2 Completed
152 enrolled 18 charts
Other neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡